Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes

被引：10

作者：

Cheng, Yugang ^{[1
]}

Zhan, Hanxiang ^{[1
]}

Wang, Lei ^{[1
]}

Xu, Jianwei ^{[1
]}

Zhang, Guangyong ^{[1
]}

Zhang, Zongli ^{[1
]}

Hu, Sanyuan ^{[1
]}

机构：

[1] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan 250012, Peoples R China

来源：

FRONTIERS OF MEDICINE | 2016年 / 10卷 / 04期

关键词：

pancreatic neuroendocrine neoplasms; clinicopathological characteristic; Ki-67; liver metastasis; outcomes; ENETS CONSENSUS GUIDELINES; ENDOCRINE TUMORS; CHROMOGRANIN-A; MANAGEMENT; DIAGNOSIS; SURVIVAL; SYSTEM;

D O I：

10.1007/s11684-016-0471-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence rate of pancreatic neuroendocrine neoplasms (pNENs) has increased rapidly in recent years. However, the clinicopathological characteristics of pNENs are poorly understood. Medical records of patients who underwent surgery and were confirmed as pNENs by pathological examination from January 2003 to February 2015 in Qilu Hospital were reviewed retrospectively. A total of 100 patients, 36 males and 64 females, were included with a mean operation age of 46.26 +/- 13.41 years. Among the 100 cases, 76 had insulinomas and 24 had non-functional pNENs. Tumor size ranged from 0.5 cm to 9 cm, and the mean size was 2.20 +/- 1.40 cm. The percentages of TNM stages I, II, III, and IV tumors were 89.0%, 8.0%, 0.0%, and 3.0%, respectively. Based on the WHO classification, pNENs were classified into three grades: G1, G2, and G3. G1, G2, and G3 tumors were confirmed in 72.9%, 23.7%, and 3.4% patients, respectively. The positive rates of CgA and Syn immunohistochemical staining were 94.5% (69/73) and 100% (74/74), respectively. Compared with insulinoma, non-functional pNENs have larger tumor sizes, more advanced TNM staging, a higher Ki-67 index, and a higher rate of liver metastasis (P < 0.05). In conclusion, pNENs are heterogeneous tumors with varying clinical manifestations, diverse tumor biological characteristics, and different prognoses. Non-functional pNENs present a more aggressive behavioral model and have poorer prognosis than functional pNENs.

引用

页码：444 / 450

页数：7

共 28 条

[11] Endocrine tumours of the pancreas [J].

Öberg, K ;

Eriksson, B .

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2005, 19 (05) :753-781

[12] Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Oberg, K. ;

Knigge, U. ;

Kwekkeboom, D. ;

Perren, A. .

ANNALS OF ONCOLOGY, 2012, 23 :124-130

[13] Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours [J].

Oberg, Kjell .

[14] Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) [J].

Ramage, John K. ;

Ahmed, A. ;

Ardill, J. ;

Bax, N. ;

Breen, D. J. ;

Caplin, M. E. ;

Corrie, P. ;

Davar, J. ;

Davies, A. H. ;

Lewington, V. ;

Meyer, T. ;

Newell-Price, J. ;

Poston, G. ;

Reed, N. ;

Rockall, A. ;

Steward, W. ;

Thakker, R. V. ;

Toubanakis, C. ;

Valle, J. ;

Verbeke, C. ;

Grossman, A. B. .

GUT, 2012, 61 (01) :6-32

[15] TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system [J].

Rindi, G. ;

Kloeppel, G. ;

Alhman, H. ;

Caplin, M. ;

Couvelard, A. ;

de Herder, W. W. ;

Erikssson, B. ;

Falchetti, A. ;

Falconi, M. ;

Komminoth, P. ;

Koerner, M. ;

Lopes, J. M. ;

McNicol, A-M. ;

Nilsson, O. ;

Perren, A. ;

Scarpa, A. ;

Scoazec, J. -Y ;

Wiedenmann, B. .

VIRCHOWS ARCHIV, 2006, 449 (04) :395-401

[16] TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study [J].

Rindi, G. ;

Falconi, M. ;

Klersy, C. ;

Albarello, L. ;

Boninsegna, L. ;

Buchler, M. W. ;

Capella, C. ;

Caplin, M. ;

Couvelard, A. ;

Doglioni, C. ;

Delle Fave, G. ;

Fischer, L. ;

Fusai, G. ;

de Herder, W. W. ;

Jann, H. ;

Komminoth, P. ;

de Krijger, R. R. ;

La Rosa, S. ;

Luong, T. V. ;

Pape, U. ;

Perren, A. ;

Ruszniewski, P. ;

Scarpa, A. ;

Schmitt, A. ;

Solcia, E. ;

Wiedenmann, B. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (10) :764-777

[17] Therapy for metastatic pancreatic neuroendocrine tumors [J].

Rossi, Roberta Elisa ;

Massironi, Sara ;

Conte, Dario ;

Peracchi, Maddalena .

ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (01)

[18] Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients [J].

Scarpa, Aldo ;

Mantovani, William ;

Capelli, Paola ;

Beghelli, Stefania ;

Boninsegna, Letizia ;

Bettini, Rossella ;

Panzuto, Francesco ;

Pederzoli, Paolo ;

delle Fave, Gianfranco ;

Falconi, Massimo .

MODERN PATHOLOGY, 2010, 23 (06) :824-833

[19] Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group [J].

Singh, Simron ;

Dey, Chris ;

Kennecke, Hagen ;

Kocha, Walter ;

Maroun, Jean ;

Metrakos, Peter ;

Mukhtar, Tariq ;

Pasieka, Janice ;

Rayson, Daniel ;

Rowsell, Corwyn ;

Sideris, Lucas ;

Wong, Ralph ;

Law, Calvin .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) :2685-2699

[20]

Singh S, 2012, EXPERT REV GASTROENT, V6, P313, DOI [10.1586/egh.12.15, 10.1586/EGH.12.15]

← 1 2 3 →